Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

1
Rumor Alert: Merck KGaA to Buy Madrigal and Roche to Acquire Tesaro?

2018-07-20 biospace
Investors love their takeover rumors, and with biopharma having a good year for mergers and acquisitions, there’s been plenty to keep them busy. Here’s two takeover rumors that came out of Spanish media group Intereconomia.
MKGAF MDGL MKGAY GILD FMI CLVS

21
Rounds Report: Gemphire Enjoyed A Robust Appreciation Backed By Strong Fundamentals

2018-07-19 seekingalpha
The bioscience market demonstrated a big comeback today following a slumbering Monday. Many equities under our coverage continued to rally and thereby procure more profits for shareholders.
ENTA MDGL GILD GLMD GEMP ICPT IBB XBI

8
Rounds Report: Galmed Rallied Subsequent To The Overweight Rating Of Dr. Elemer Piros

2018-07-15 seekingalpha
The overall bioscience market ended the second week of July with a mixed sentiment. Nevertheless, many equities under our coverage continued to rally and thereby procured more profits.
INFI MDGL GLMD IBB XBI

22
Gemphire: Is There More To This Strong Grower?

2018-07-13 seekingalpha
Gemcabene is being innovated in various franchises including nonalcoholic fatty liver disease (“NAFLD”)/nonalcoholic steatohepatitis (“NASH”) and dyslipidemias.
ENTA MDGL GILD GLMD GEMP ICPT

49
Innovate: Are There Further Upsides From This Robust Grower?

2018-07-13 seekingalpha
As a momentum stock, Innovate’s shares gained over 100% in just two weeks. A fundamental analysis to reveal whether there are further upsides.
ENTA MDGL GILD INNT GLMD ICPT

3
Viking Therapeutics: Thesis Strengthens, Catalysts In Focus

2018-07-10 seekingalpha
Shares have risen by 160% since my initial article and also performed well as an ROTY Contender.
MDGL VKTXW VKTX

7
Galmed Pharmaceuticals: Strong Fundamentals Powering A NASH Innovator

2018-07-06 seekingalpha
Galmed is advancing its novel molecule (Aramchol) for the management of nonalcoholic steatohepatitis. Aramchol demonstrated strong preclinical and clinical data thus far.
ENTA MDGL GILD GLMD ICPT

5
Best ETFs for 2018: ALPS Medical Breakthroughs ETF Keeps Rolling Along

2018-07-02 investorplace
This article is a part of InvestorPlace’s Best ETFs for 2018 contest. Todd Shriber’s pick for the contest is the ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO).
MDGL SBIO GWPH GWP

128
Gemphire's Positive Phase 2b Results Reignites The NASH Market Yet Again

2018-07-02 seekingalpha
Gemphire Therapeutics obtains positive phase 2b results in treating patients with severe Hypertriglyceridemia (high levels of triglycerides) using its drug gemcabene.
MDGL VKTXW HGRL GILD CNAT GLMD GEMP ICPT VKTX

39
Rounds Report: Intercept Pharmaceuticals Is Making A Slow And Steady Comeback

2018-07-01 seekingalpha
The overall bioscience market ended the week on a positive note. Despite their small gains, many equities under our coverage continued to procure profits for investors.
MDGL ARPO ICPT IBB XBI

26
Global Blood Therapeutics: What The Recent HOPE-KIDS 1 Data Foretells

2018-06-22 seekingalpha
Company reported data from the phase 2A (HOPE-KIDS 1) trial that studied voxelotor as a potential treatment for sickle cell disease at EHA. The data is quite robust.
MDGL GBT

234
Institutional Top Ideas: Cormorant Asset Management

2018-06-16 seekingalpha
Cormorant Asset Management has overweighted its top 5 positions (especially first 3) and a relatively high turnover compared to other funds we´ve looked at.
OMER VSAR RXDX MDGL IDRAW IDRA GLMD

453
Avoiding The 'Black Hole' Of Disease Development

2018-06-15 seekingalpha
Both large and small concerns continue to see nothing but failure in the Alzheimer's space despite spending billions on development efforts.
MDGL GILD AZN GLMD ICPT LLY VKTX VTVT VKTXW AZN JNJ MRK CNAT ABBV ABBV AXON

3
Galmed Pharmaceuticals: Is The Pop Justified?

2018-06-14 seekingalpha
Galmed Pharmaceuticals announced positive top-line 52-week data from their phase 2b ARREST study evaluating their main asset Aramchol in the treatment of NASH.
MDGL GLMD

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to MDGL / Madrigal Pharmaceuticals, Inc. on message board site Silicon Investor.

Madrigal Pharmaceuticals
CUSIP: 87162T206